MorphoSys bags €446m licensing deal with GSK for RA candidate
This article was originally published in Scrip
GlaxoSmithKline has licensed German company MorphoSys' most advanced unpartnered product candidate, MOR103, for €22.5m up front and potential milestone payments of up to €423m. MOR103 is a HuCAL?derived antibody against GM?CSF (granulocyte-macrophage colony-stimulating factor), which has concluded Phase I/II development in mild-to-moderate rheumatoid arthritis.
You may also be interested in...
The UK's main reimbursement bodies made a series of decisions this week that were broadly favorable and largely focused on oncology medicines.
While troubled Valeant was divesting iNova to private equity investors, Novartis announced a pair of oncology-focused deals, out-licensing a brain cancer drug to Midatech and partnering with IBM Watson Health to optimize breast cancer treatment.
Astellas and Pfizer have amended the PROSPER trial protocol in a bid to position Xtandi ahead of Zytiga in the early stage prostate cancer market.